FDA
-
-
-
-
-
-
-
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
-
-
-
-
-
-
-
Priovant reports positive Phase 2 results for brepocitinib in skin condition
-
-
-
-
-
-
-
Immunovant (IMVT) Announces Leadership Changes
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
-
-
-
-
-
-
-
Roivant Sciences (ROIV) Appoints Mayukh Sukhatme to its Board
-
-
-
-
-
-
-
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
-
-
-
-
-
-
-
Roivant Sciences Announces Change to its Board of Directors
-
323,567 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

